Antimicrobial & Immunization for Bacterial Gastritis

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI060028-01A1
Agency Tracking Number: AI060028
Amount: $104,372.00
Phase: Phase I
Program: SBIR
Awards Year: 2005
Solicitation Year: 2005
Solicitation Topic Code: N/A
Solicitation Number: PHS2005-2
Small Business Information
AMARILLO BIOSCIENCES, INC.
Amarillo Biosciences, Inc., 4134 Business Park Dr, Amarillo, TX, 79110
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOSEPH CUMMINS
 (806) 376-1741
 JCUMMINS@AMARBIO.COM
Business Contact
 JOSEPH CUMMINS
Phone: (806) 376-1741
Email: JCUMMINS@AMARBIO.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Helicobacter pylori (Hp), a gastric bacterial pathogen of humans; infection is the cause of type B gastritis and is also strongly associated with gastric carcinoma (intestinal type) and gastric MALT lymphoma. Combination antimicrobial therapy (triple therapy with a bismuth salt, metranidazole and a broad spectrum antibiotic) is successful in 80% of Hp-infected symptomatic patients; treatment failures are expressed as recrudescence of infection and clinical signs and are associated with development of antibiotic-resistant microbes and poor patient compliance. In a previous SBIR, we have demonstrated that parenteral immunization with an Hp proteolytic digest prevents colonization in Hp-challenged gnotobiotic swine. Preliminary data suggest that activated T cells and their products, in particular, interferon gamma (IFNg), are central for this immunoprotective effect. An ideal approach to the problem of recrudescence treatment failure is to combine antimicrobial therapy with parenteral immunization in the post-treatment interval when Hp colonization levels are low to nonexistent yet the risk of eventual recurrence is real. In this SBIR proposal, we will test the hypothesis that parenteral immunizations of piglets, temporarily cleared or eradicated of infection with selected antimicrobials, will resist re-challenge inoculation with Hp. In addition, we will test the hypotheses that the mechanism of protection is, in part, mediated by IFNg and that orally administered IFNg will prevent recrudescence and may even replace current antimicrobial regimens if a positive therapeutic effect in actively infected piglets can be achieved. From these data, the feasibility of a combined antimicrobial and immunization approach for the successful treatment of symptomatic Hp disease in humans will be discerned. If these data are positive, a phase II SBIR application will be prepared to capitalize on these findings for the commercial development of this novel approach to Hp-associated gastric infection.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government